NextFin News - Shares of French biotechnology firm Abivax plummeted as much as 32% on Tuesday after the company released long-term maintenance data for its lead drug candidate, obefazimod. While the trial met its primary efficacy endpoints for treating ulcerative colitis, the report of three cancer cases among patients receiving the higher dose triggered a massive sell-off, overshadowing the drug’s clinical performance and casting a shadow over the company’s status as a prime takeover target.
The sell-off erased a significant portion of the gains Abivax had accumulated following a stellar 2025, during which the stock surged nearly 1,700% on the back of mid-stage trial successes. According to data published late Monday, the 44-week maintenance study showed a remission rate of approximately 40% for both doses tested. However, the emergence of a "cancer signal" in the high-dose group has immediately shifted the narrative from the drug’s potential as a "best-in-class" treatment to a debate over its long-term safety profile.
A Jefferies analyst noted that the cancer signal "complicates matters" significantly for the clinical-stage biotech. The analyst, who has historically maintained a cautious but data-driven stance on the sector, emphasized that even if these cases eventually prove to be "unrelated noise," the overhang on the stock will be persistent. This skepticism is particularly acute given the absence of other major value-inflecting data events scheduled for the next twelve months, leaving the stock vulnerable to prolonged sentiment-driven pressure.
The Jefferies view, while influential in the immediate aftermath of the data release, does not yet represent a unanimous consensus across the sell-side. Some institutional investors may view the 30% drop as an overreaction, especially if the cancer cases are later determined to be linked to patient history rather than the drug’s mechanism. However, the burden of proof has shifted to Abivax management to demonstrate that obefazimod—which is also being tested for Crohn’s disease—remains a viable candidate for the multi-billion-dollar irritable bowel syndrome market.
The timing of the safety concern is particularly sensitive for U.S. President Trump’s administration, which has prioritized domestic pharmaceutical competition and streamlined drug approvals. While Abivax is a French company, its heavy reliance on the U.S. market for future commercialization and its Nasdaq listing make it a bellwether for the broader biotech M&A landscape. Unconfirmed speculation had previously linked several large pharmaceutical companies to a potential acquisition of Abivax, but such a deal now appears stalled until the safety data can be further clarified.
From a clinical perspective, the trial results present a paradox. The efficacy data remains robust, with clinical remission rates significantly outperforming historical placebo benchmarks. Yet, in the high-stakes world of immunology, where several established treatments already exist, any hint of malignancy can be a commercial death sentence. The company had previously reported no new safety signals as recently as late 2025, making the sudden appearance of these cases in the 44-week data a jarring reversal for shareholders.
The path forward for Abivax now depends on the detailed patient-level analysis of the three cancer cases. If the company can prove these were pre-existing conditions or unrelated to the drug's pharmacological action, the stock may recover some of its lost ground. Conversely, if regulatory bodies like the FDA or EMA request additional long-term safety trials, the timeline for a U.S. filing—previously planned for late 2026—could be pushed back indefinitely, further cooling any remaining interest from potential acquirers.
Explore more exclusive insights at nextfin.ai.
